Brainomix AI shows its worth in AZ pulmonary fibrosis trial

Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinical trial of AstraZeneca’s experimental therapy tralokinumab.